Tailoring neo/adjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations

Elghazaly et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68e60bf9b6db64358759f463 — DOI: https://doi.org/10.1002/cncr.35389

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)· 2021 · 9 citations
2. Contrast-enhanced spectral mammography vs. mammography and MRI – clinical performance in a multi-reader evaluation· 2016 · 243 citations
3. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).· 2020 · 123 citations
4. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)· 2013 · 1,260 citations
5. Staging of Breast Cancer· 1981 · 98 citations